Pulmonary arterial hypertension requires vigilant monitoring beyond just a superficial conversation, including several yearly tests and analyses, according to Simon Gibbs, MD, Reader in Pulmonary Hypertension at the National Heart and Lung Institute, Imperial College London.
Pulmonary arterial hypertension requires vigilant monitoring beyond just a superficial conversation, including several yearly tests and analyses, according to Simon Gibbs, MD, Reader in Pulmonary Hypertension at the National Heart and Lung Institute, Imperial College London.
Transcript
What are the challenges of daily management of patients with pulmonary arterial hypertension?
The most important thing with pulmonary arterial hypertension is getting the diagnosis right. And then, having made a diagnosis, they require treatment, and they require support. The treatment with the drug therapies requires very vigilant follow-up over time, as long as the patients are on treatment and the treatments are in general for life.
So, they will require follow-up every 3 to 6 months, usually at 3-monthly intervals. It’s not a matter of just sitting with a patient and saying, “Hey, how are you? Can you walk and all the rest of it? That’s fine, off you go.” It’s also critical to undertake further investigations and it’s not necessarily everything every time, but that includes blood test, 6 minute walk test, arterial blood gases or oxygen saturation, echocardiography, cardiopulmonary exercise testing, and measuring hemodynamics by right-heart catheterization.
So it’s not every visit, but at least at our institution we undertake an annual assessment once a year and do everything. If a patient changes treatment or a dose is changed, then everything is repeated after 3 or 4 months. It isn’t just a simple, “Hi, how are you getting on?” and I think that’s the important thing.
But in addition to that, the patients require support. They go to other healthcare professionals and have other medical conditions, of course, and then nobody knows whether it’s safe to do something to them or not, or to give them this drug or that drug. They all come running along, saying, can I do this, can I do that, and other doctors do the same. So there’s a lot of remote telephone support, and then there’s also seeing the patient as well.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More